Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.880 +0.010 (+0.53%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	797,583
Open	1.860
Bid (Size)	1.880 (100)
Ask (Size)	1.890 (900)
Prev. Close	1.870
Today's Range	1.800 - 1.895
52wk Range	0.6600 - 3.535
Shares Outstanding	60,705,391
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

November 12, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

November 03, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Performance

YTD	+11.9%	+11.9%
1 Month	-23.3%	-23.3%
3 Month	-5.1%	-5.1%
6 Month	+67.9%	+67.9%
1 Year	-6.9%	-6.9%

More News

Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside

November 03, 2025

Via AB Newswire

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments ↗

November 03, 2025

Via Stocktwits

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today? ↗

November 03, 2025

Via Benzinga

Gapping stocks in Monday's session ↗

November 03, 2025

Via Chartmill

Discover the top movers in Monday's pre-market session. ↗

November 03, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 03, 2025

Via Benzinga

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

November 03, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

November 03, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket ↗

November 03, 2025

Via Benzinga

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

November 02, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors

October 04, 2025

Via MarketMinute

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

August 25, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Inc (NASDAQ:CRBU) Posts Mixed Q2 2025 Earnings with Revenue Beat but Wider Loss ↗

August 12, 2025

Via Chartmill

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 25, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering ↗

June 20, 2025

Via Benzinga

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

May 28, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 08, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

May 06, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

April 24, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 10, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

March 06, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

CRBU DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important February 24 Deadline in Securities Class Action - CRBU

February 19, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Frequently Asked Questions

Is Caribou Biosciences, Inc. - Common Stock publicly traded?

Yes, Caribou Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Caribou Biosciences, Inc. - Common Stock trade on?

Caribou Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Caribou Biosciences, Inc. - Common Stock?

The ticker symbol for Caribou Biosciences, Inc. - Common Stock is CRBU on the Nasdaq Stock Market

What is the current price of Caribou Biosciences, Inc. - Common Stock?

The current price of Caribou Biosciences, Inc. - Common Stock is 1.880

When was Caribou Biosciences, Inc. - Common Stock last traded?

The last trade of Caribou Biosciences, Inc. - Common Stock was at 11/26/25 04:00 PM ET

What is the market capitalization of Caribou Biosciences, Inc. - Common Stock?

The market capitalization of Caribou Biosciences, Inc. - Common Stock is 114.13M

How many shares of Caribou Biosciences, Inc. - Common Stock are outstanding?

Caribou Biosciences, Inc. - Common Stock has 114M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.